BioSpace News Archive

Advice from an Executive: How to Become a Leader in the Life Sciences

Eliseo Salinas, M.D., head of R&D for Delix Therapeutics offers his perspective on what it takes to become a leader in the life sciences and how to begin that transition.

October 7, 2022
·
5 min read
·
Gail Dutton
FDA

FDA Expands Label for Alnylam’s Oxlumo for Sickest Patients with Rare Disease PH1

The FDA approved Alnylam’s Oxlumo for an expanded indication, rare disease PH1, with the label to include patients with the most severe kidney impairment.

October 7, 2022
·
3 min read
·
Mark Terry
Business

BioMarin, Cyclerion Slash Workforce in the Name of Strategic Focus

BioMarin Pharmaceuticals announced Friday it was shedding around 4% of its global workforce, or around 120 jobs, in an effort to improve its operational efficiency.

October 7, 2022
·
3 min read
·
Tristan Manalac
Research Roundup: Ancestry in Cancer Treatment, Nanotech, Genetic Diseases and More

This week, researchers presented findings in how ancestry affects cancer treatment, nanotechnology and genetic diseases. Here’s a look at that and more.

October 7, 2022
·
3 min read
·
Katherine Davis
Business

Schrödinger, Eli Lilly Strike $425M Small Molecule Deal

Computational technology company Schrödinger announced Thursday it has forged a $425 million drug design collaboration with Eli Lilly.

October 7, 2022
·
2 min read
·
Alex Keown
Drug Development

Evommune’s Human Tissue-based Approach Enables Discovery and Development of Safer, Innovative Chronic Inflammation Therapies

Evommune’s novel human tissue-based assay system is proving to be a key differentiator as the company develops therapies to control chronic inflammation in autoimmune diseases.

October 7, 2022
·
7 min read
·
Gail Dutton
Drug Development

Allogene Initiates First-Ever Phase II Trial of Allogeneic CAR-T Therapy

Allogene Therapeutics is launching what it calls the first pivotal Phase II trial of an allogeneic CAR T product in the industry. The ALPHA2 trial will evaluate ALLO-501A in LBCL.

October 7, 2022
·
3 min read
·
Mark Terry
Job Trends

Amgen, Enzo BioChem and Amphista Therapeutics Open New Facilities (Updated)

Amgen opened a new research and development site in San Francisco Bay, while Enzo Biochem opened a 100,000 square foot laboratory and research facility in New York

October 7, 2022
·
3 min read
·
Alex Keown
Drug Development

FDA Review: Alnylam, Cytokinetics, Eli Lilly and More

The FDA had a fairly quiet week, approving drugs, providing clearance, greenlighting clinical trials, and other regulatory activities for Alnylam, Eli Lilly, Cytokinetics, and more.

October 7, 2022
·
3 min read
·
Mark Terry
Business

CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch

CytoSorbents Corporation announced today that its Chief Financial Officer, Kathleen P. Bloch , MBA, CPA, plans to retire on March 31, 2023 at age 68, following a distinguished decade-long career at the Company.

October 7, 2022
·
8 min read